Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia

Abstract Refractory/relapsed B-cell acute lymphoblastic leukemia remains to be a significant cause of cancer-associated morbidity and mortality for children and adults. Developing novel and effective molecular-targeted approaches is thus a major priority. Chimeric antigen receptor-modified T cell (C...

Full description

Bibliographic Details
Main Authors: Guoqing Wei, Lijuan Ding, Jiasheng Wang, Yongxian Hu, He Huang
Format: Article
Language:English
Published: BMC 2017-04-01
Series:Experimental Hematology & Oncology
Subjects:
Acute lymphoblastic leukemia (ALL)
CD19
Chimeric antigen receptor-modified T cell (CAR-T)
Conditioning regimen
Complication
Cytokine release syndrome (CRS)
Online Access:http://link.springer.com/article/10.1186/s40164-017-0070-9

Internet

http://link.springer.com/article/10.1186/s40164-017-0070-9

Similar Items